Alzinova AB

Alzinova's ALZ-101 Vaccine Advances to Phase 2 Trial Following Successful Drug Substance Production

- Alzinova AB has successfully released the drug substance for its ALZ-101 vaccine candidate, enabling final drug product manufacturing for an upcoming Phase 2 clinical trial in early Alzheimer's disease scheduled to begin in the second half of 2025. - The Phase 1b clinical trial results for ALZ-101 demonstrated a favorable safety profile, strong immune response against toxic amyloid-beta oligomers, and promising early signals of disease stabilization in patients with early Alzheimer's disease. - Produced by Polypeptide Laboratories under GMP standards, the partnership will continue to optimize manufacturing processes for late-stage clinical trials, focusing on enhancing production efficiency and scalability for potential commercialization.